- Home
- KRON vs INZY Comparison
KRON vs INZY Comparison
Compare KRON & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- INZY
- Stock Information
- Founded
- KRON 2017
- INZY 2015
- Country
- KRON United States
- INZY United States
- Employees
- KRON N/A
- INZY N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- KRON Health Care
- INZY Health Care
- Exchange
- KRON Nasdaq
- INZY Nasdaq
- Market Cap
- KRON 61.5M
- INZY 64.9M
- IPO Year
- KRON 2020
- INZY 2020
- Fundamental
- Price
- KRON $0.83
- INZY $0.92
- Analyst Decision
- KRON Buy
- INZY Strong Buy
- Analyst Count
- KRON 3
- INZY 10
- Target Price
- KRON $1.63
- INZY $16.90
- AVG Volume (30 Days)
- KRON 165.9K
- INZY 522.9K
- Earning Date
- KRON 03-18-2025
- INZY 03-10-2025
- Dividend Yield
- KRON N/A
- INZY N/A
- EPS Growth
- KRON N/A
- INZY N/A
- EPS
- KRON N/A
- INZY N/A
- Revenue
- KRON $9,848,000.00
- INZY N/A
- Revenue This Year
- KRON N/A
- INZY N/A
- Revenue Next Year
- KRON N/A
- INZY N/A
- P/E Ratio
- KRON N/A
- INZY N/A
- Revenue Growth
- KRON 56.62
- INZY N/A
- 52 Week Low
- KRON $0.69
- INZY $0.91
- 52 Week High
- KRON $1.60
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- KRON 27.47
- INZY 32.69
- Support Level
- KRON $0.82
- INZY $0.94
- Resistance Level
- KRON $0.95
- INZY $1.05
- Average True Range (ATR)
- KRON 0.06
- INZY 0.08
- MACD
- KRON -0.01
- INZY 0.01
- Stochastic Oscillator
- KRON 3.12
- INZY 5.37
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Inc is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting bone health and blood vessel function. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, genetically engineered fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 deficiencies.